Brazil Congressman Sees Cannabis Cultivation Bill Making Progress in December

RIO DE JANEIRO, BRAZIL – A Brazilian bill that would legalize medical marijuana and industrial hemp cultivation could soon have its first debate on the floor of the lower house of Congress, ahead of its expected approval in that chamber before the end of this year, federal deputy Paulo Teixeira (PT-SP) told Marijuana Business Daily.

The bill, PL 399/2015, would have far-reaching implications for Latin America’s largest medical cannabis market, which currently is dependent on imported products.

The current high price of imported medical cannabis has been one of the main arguments in favor of the cultivation bill: Proponents say domestic growers would be able to supply the medicine at a lower cost.

According to Teixeira, who leads a medical cannabis special committee in the lower house, the bill failed to advance through the legislative process in recent months, mainly because the country’s municipal elections “paralyzed parliamentary work.”

“With these elections behind us, I expect the lower house to quickly start debating and approve the bill before the end of the year,” the deputy told MJBizDaily.

He further said the proposed law is “the result of a long and profound debate that considered the best of different cannabis legislations in other countries.”

To become law, the bill also requires Senate approval, which Teixeira said could happen sometime next year. He does not anticipate major changes in the bill being needed to secure its final passage.

Asked by MJBizDaily about the possibility of President Jair Bolsonaro opposing the reform, Teixeira said it will be “difficult” because the bill has broad support.

Next week, however, the National Committee for Health Technology Incorporation (Conitec) will meet to evaluate the inclusion of one specific formulation of Cannabidiol (CBD) in the National Health System (SUS).

A final decision, expected in early 2021, could make patients eligible to receive public health coverage for that CBD formulation, effectively making it free of charge.

That product, manufactured by Brazilian pharmaceutical firm Prati-Donaduzzi with imported raw material, is the only one that has received “sanitary authorization” from the National Health Regulatory Agency (ANVISA).

It is the only product available in pharmacies, but at a cost of R$2,000 ($375) or more, it remains unaffordable for many patients, which has limited the market.

If the CBD product became available to patients free of charge, it could undermine cannabis industry advocates who argue domestic-grown medicine is needed to provide patients with less expensive medical marijuana.

“By including a CBD formulation into SUS coverage, the government, which is largely against the bill, could diminish one of the main arguments for the proposed legislation,” José Bacellar, CEO of Toronto-based VerdeMed, a company focused on the Brazilian market, told MJBizDaily.

“We cannot expect taxpayers to have to cover the bill of such an expensive CBD product,” Deputy Teixeira said.

Source: Marijuana Business Daily